Inside HDACs with more selective HDAC inhibitors
J Roche, P Bertrand - European journal of medicinal chemistry, 2016 - Elsevier
Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal
mainly against cancers, with four compounds approved by the Food and Drug …
mainly against cancers, with four compounds approved by the Food and Drug …
HDAC6: A unique HDAC family member as a cancer target
S Kaur, P Rajoria, M Chopra - Cellular Oncology, 2022 - Springer
Background HDAC6, a structurally and functionally distinct member of the HDAC family, is
an integral part of multiple cellular functions such as cell proliferation, apoptosis …
an integral part of multiple cellular functions such as cell proliferation, apoptosis …
Histone deacetylase 6 in health and disease
C Seidel, M Schnekenburger, M Dicato… - Epigenomics, 2015 - Taylor & Francis
Histone deacetylase (HDAC) 6 is a member of the class IIb HDAC family. This enzyme is
zinc-dependent and mainly localized in the cytoplasm. HDAC6 is a unique isoenzyme with …
zinc-dependent and mainly localized in the cytoplasm. HDAC6 is a unique isoenzyme with …
Strategies to design selective histone deacetylase inhibitors
J Melesina, CV Simoben, L Praetorius… - …, 2021 - Wiley Online Library
This review classifies drug‐design strategies successfully implemented in the development
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …
Next-generation of selective histone deacetylase inhibitors
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer
treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of …
treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of …
Recent advances in the discovery of potent and selective HDAC6 inhibitors
XX Wang, RZ Wan, ZP Liu - European journal of medicinal chemistry, 2018 - Elsevier
Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among
HDAC enzymes in having two active catalytic domains, and has unique physiological …
HDAC enzymes in having two active catalytic domains, and has unique physiological …
Recent progress in histone deacetylase inhibitors as anticancer agents
Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …
The search for potent, small‐molecule HDACIs in cancer treatment: a decade after vorinostat
C Zagni, G Floresta, G Monciino… - Medicinal research …, 2017 - Wiley Online Library
Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are
involved in the epigenetic regulation of gene expression. In the last decade, inhibition of …
involved in the epigenetic regulation of gene expression. In the last decade, inhibition of …
Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors
K Vögerl, N Ong, J Senger, D Herp… - Journal of medicinal …, 2019 - ACS Publications
The phenothiazine system was identified as a favorable cap group for potent and selective
histone deacetylase 6 (HDAC6) inhibitors. Here, we report the preparation and systematic …
histone deacetylase 6 (HDAC6) inhibitors. Here, we report the preparation and systematic …
How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin a enantiomers based on molecular dynamics
Y Zhang, JB Ying, JJ Hong, FC Li, TT Fu… - ACS Chemical …, 2019 - ACS Publications
Histone deacetylase 6 (HDAC6) plays a key role in a variety of neurological disorders, which
makes it attractive drug target for the treatment of Alzheimer's disease, Parkinson's disease …
makes it attractive drug target for the treatment of Alzheimer's disease, Parkinson's disease …